Evidence map›Paper›PMID 40089517›Full record

ArticleScientific reports2025

Genetic instability in HSPC subpopulations of umbilical cord blood from patients with childhood acute lymphoblastic leukemia.

Katarina Vrobelova, Lukas Jakl, Milan Skorvaga, Pavol Kosik, Matus Durdik, Eva Markova, Jana Jakubikova, Marek Holop, Miroslav Kubes, Martin Cermak and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Katarina Vrobelova *Department of Radiobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia.
Lukas Jakl *Department of Radiobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia.
Milan SkorvagaDepartment of Radiobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia.
Pavol KosikDepartment of Radiobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia.
Matus DurdikDepartment of Radiobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia.
Eva MarkovaDepartment of Radiobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia.
Jana JakubikovaDepartment of Tumor Immunology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
Marek HolopStem Cell Lab, BIOM-R, Ltd., Bratislava, Slovakia.
Miroslav KubesStem Cell Lab, BIOM-R, Ltd., Bratislava, Slovakia.
Martin CermakDepartment of Genetics, National Cancer Institute, Bratislava, Slovakia.
Judita PuskacovaDepartment of Pediatric Hematology and Oncology, National Institute of Children´S Diseases and Medical Faculty, Comenius University, Bratislava, Slovakia.
Alexandra KolenovaDepartment of Pediatric Hematology and Oncology, National Institute of Children´S Diseases and Medical Faculty, Comenius University, Bratislava, Slovakia.
Igor BelyaevDepartment of Radiobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia. igor.beliaev@savba.sk.

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-15-0250Operational Programme Integrated Infrastructure for the project: Strengthening of Research, Development and Innovation Capacities of Translational Biomedical Research of Human Diseases ITMS: 313021BZC9Vedecká Grantová Agentúra MŠVVaŠ SR a SAV VEGA 2/0138/22
6 · The paper itself

Abstract

Preleukemic stem cells (PSC) containing preleukemic fusion genes (PFG) arise prenatally and represent the initial stage of acute lymphoblastic leukemia (ALL) development. Despite widespread efforts, the cell of origin of PFG is still unclear. For the first time, in order to identify the immunophenotype of the PSCs, different subpopulations of hematopoietic stem and progenitor cells (HSPC) of umbilical cord blood (UCB) from ALL pediatric patients and control healthy children were sorted and analyzed for the presence of diagnostically-relevant PFGs by fluorescent in situ hybridization (FISH). Representative FISH results were confirmed by RT-qPCR and validated by sequencing of the products. Not only did we identify likely subpopulations of TEL/AML1+ PSC to be CD34+ CD38+ and CD34+ CD38- cells, but we also found markedly increased instability of often associated with ALL genes in UCB HSPC subpopulations of ALL pediatric patients. Our data show that CD34+ CD38+ as well as CD34+ CD38- cells are prone to genetic instability and most likely represent the target for malignant transformation in the development of ALL. Overall, together with confirming the prenatal origin of PFGs, this study provides further insight into the preleukemic stage of ALL and shows that ALL is a potentially screen able disease.

Indexed as

Fetal BloodGenomic InstabilityHematopoietic Stem CellsPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentADP-ribosyl Cyclase 1Antigens, CD34ChildChild, PreschoolCore Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinFemaleHumansImmunophenotypingInfantIn Situ Hybridization, FluorescenceADP-ribosyl Cyclase 1Antigens, CD34Core Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinOncogene Proteins, FusionTEL-AML1 fusion protein

Identifiers

PMID40089517
PMCPMC11910527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.